AstraZeneca's Baxfendy Wins Positive EMA Recommendation for Hypertension

MT Newswires Live11-13 20:12

AstraZeneca's (AZN) Baxfendy, developed for the treatment of adults with insufficiently controlled hypertension, has been recommended for marketing authorization by the European Medicines Agency's Committee for Medicinal Products for Human Use, the agency said Friday.

The health agency said the recommendation is based on clinical trials showing statistically significant reductions in systolic and diastolic blood pressure compared with placebo in patients whose hypertension remained uncontrolled despite treatment with at least two medications.

The European Commission will make the final decision on marketing authorization, the agency said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment